drugset / Trial / NCT01276106

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

NCT01276106

Phase 2 Completed 259 enrolled TWi Biotechnology, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.

Timeline

Start
2011-01
Primary completion
2012-02
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Diacerein Small molecule 25 mg Oral
Subject Diacerein Small molecule 50 mg Oral
Subject Diacerein Small molecule 75 mg Oral